U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H20Cl2F2N2O2S
Molecular Weight 497.385
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DRINABANT

SMILES

CS(=O)(=O)N(C1CN(C1)C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)C4=CC(F)=CC(F)=C4

InChI

InChIKey=IQQBRKLVEALROM-UHFFFAOYSA-N
InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3

HIDE SMILES / InChI

Molecular Formula C23H20Cl2F2N2O2S
Molecular Weight 497.385
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Drinabant is a selective CB1 receptor antagonist under investigation varyingly as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Drinabant may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. Coadministration of olanzapine and drinabant attenuated body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility. Sanofi has outlicensed global development and commercialization rights to drinabant to Opiant Pharmaceuticals, which said it plans to start developing the acute cannabinoid overdose (ACO) candidate in the 2019 year. Opiant said drinabant will be developed as an injectable for administration in an emergency department setting.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.68 nM [Ki]
PubMed

PubMed

TitleDatePubMed
CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.
2007 Sep
Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
2010 Oct
Patents

Sample Use Guides

10 mg/kg once daily
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:59:53 UTC 2023
Edited
by admin
on Sat Dec 16 16:59:53 UTC 2023
Record UNII
61S98RLL5I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DRINABANT
INN   WHO-DD  
INN  
Official Name English
drinabant [INN]
Common Name English
Drinabant [WHO-DD]
Common Name English
Code System Code Type Description
INN
9033
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
PUBCHEM
10278470
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
ChEMBL
CHEMBL3545166
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
FDA UNII
61S98RLL5I
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
EPA CompTox
DTXSID50189455
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
NCI_THESAURUS
C166890
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
DRUG BANK
DB05750
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
MESH
C523652
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
WIKIPEDIA
Drinabant
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
SMS_ID
300000036929
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
CAS
358970-97-5
Created by admin on Sat Dec 16 16:59:53 UTC 2023 , Edited by admin on Sat Dec 16 16:59:53 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY